Rocket Pharma - RCKT Company profit before taxes, interest and amortization
Rocket Pharmaceuticals' business is independent of macroeconomic cycles, as demand for gene therapy remains stable. The absolute cash result of operations demonstrates capital's reaction to the company's efficiency, where 0.00 forms the current metric. Despite a solid liquidity cushion for product launches, risks of FDA delays and manufacturing scaling challenges persist.
Rocket Pharmaceuticals, Inc. (RCKT) - metric breakdowns and financial figures
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Rocket Pharmaceuticals|RCKT - Long-Term Debt to Capital|Short-Term Debt to Capital Rocket Pharma|RCKT - Company Debts|Debt to Net Assets Ratio Rocket Pharmaceuticals|RCKT - Company Long-Term Debt|Company Current Liabilities Rocket Pharmaceuticals|Quick Ratio rocketpharma.com
- earnings and market ratios statistics:
RCKT - Net Profit|Future Profit Rocket Pharmaceuticals|RCKT - P/E Multiple|Projected Price to Earnings Ratio rocketpharma.com|RCKT - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Rocket Pharmaceuticals|RCKT - Operating profit before deduction of amortization|Earnings per share for the last four quarters Rocket Pharmaceuticals|RCKT - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months rocketpharma.com|RCKT - Earnings growth in current year|Expected earnings per share growth for next year Rocket Pharmaceuticals
Analysis of all company metrics:Rocket Corp
This indicator captures actual cash flows from core operations, allowing for the differentiation of sustainable growth from short-term anomalies through the analysis of historical extremes. By examining the EBITDA chart, an investor assesses the scaling efficiency of Rocket Pharmaceuticals (RCKT) production capacities, which is critical as the company transitions to the autonomous manufacture of therapies for rare cardiac and blood diseases.
Competitors of Rocket Pharmaceuticals (RCKT)
Tempus (TEM) - Profit before interest, taxes and amortization|QGEN: Operating profit before deduction of amortization|ionispharma.com - Company profit before taxes, interest and amortization|RGEN (Repligen) - Operating profit before deduction of amortization|Avidity Biosciences Inc - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization CRISPR Therapeutics Corp|GeneDx Corp - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA RARE|BEAM (beamtx.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA SRPT (Sarepta)|Operating profit EBITDA Twist Bioscience Inc TWST|TXG - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization NTLA (Intellia Corp)|Stoke Therapeutics (STOK) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization biolifesolutions.com|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Operating profit EBITDA Maze Therapeutics, Inc.|Operating profit EBITDA SION|Operating profit before deduction of amortization Prime Medicine Bio PRME|Operating profit EBITDA TSHA (Taysha Gene Therapies)|uniqure.com (QURE) - Profit before interest, taxes and amortization|MGTX: Operating profit before deduction of amortization|RGNX - Operating profit EBITDA|SLDB (Solid Bio) - Operating profit before deduction of amortization|OCGN: Company profit before taxes, interest and amortization|PACB (Pacific Biosciences) - Operating profit EBITDA|benitec.com (BNTC) - Operating income before deduction of amortization|Operating profit EBITDA DSGN|Operating profit before deduction of amortization 4DMT FDMT|Operating profit EBITDA LXEO (Lexeo Therapeutics, Inc.)|Operating profit EBITDA Korro Bio Inc. KRRO|EDIT - Profit before payment of interest, taxes and amortization|SLN: Profit before payment of interest, taxes and amortization|proqr.com (PRQR) - Profit before payment of interest, taxes and amortization|CDXS - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Sangamo|NAUT: Income before deduction of interest, taxes and amortization|Operating profit EBITDA MGX|Operating profit before deduction of amortization precisionbiosciences.com DTIL|Profit before payment of interest, taxes and amortization Generation Bio GBIO|Operating profit EBITDA Boundless Bio Inc. BOLD|XCUR: Operating profit before deduction of amortization|Imunon, Inc. - Company profit before taxes, interest and amortization|PHIO: Operating profit EBITDA|Operating profit before amortization MBIO|Profit before payment of interest, taxes and amortization TransCode Therapeutics Inc.|Operating profit before amortization BNGO (Bionano)|Operating profit EBITDA APDN|Operating profit EBITDA bluebird bio, Inc (BLUE)|Profit before payment of interest, taxes and amortization ImmunoPrecise Antibodies Ltd. IPA|Income before deduction of interest, taxes and amortization OMGA|OMIC - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Regulus Therapeutics, Inc.|SYRS: Operating profit EBITDA|Operating profit before deduction of amortization Telesis Bio, Inc|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|Operating profit EBITDA unitybiotechnology.com
